+

WO2008145732A1 - Compositions pharmaceutiques non aqueuses stables - Google Patents

Compositions pharmaceutiques non aqueuses stables Download PDF

Info

Publication number
WO2008145732A1
WO2008145732A1 PCT/EP2008/056699 EP2008056699W WO2008145732A1 WO 2008145732 A1 WO2008145732 A1 WO 2008145732A1 EP 2008056699 W EP2008056699 W EP 2008056699W WO 2008145732 A1 WO2008145732 A1 WO 2008145732A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
insulinotropic peptide
glp
peptide
composition according
Prior art date
Application number
PCT/EP2008/056699
Other languages
English (en)
Inventor
Simon Bjerregaard Jensen
Svend Havelund
Florian Anders FÖGER
Bernd W. Müller
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to US12/601,345 priority Critical patent/US20100190706A1/en
Priority to JP2010509835A priority patent/JP5675347B2/ja
Priority to EP08760287A priority patent/EP2164459A1/fr
Publication of WO2008145732A1 publication Critical patent/WO2008145732A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Definitions

  • the present invention relates to non-aqueous pharmaceutical compositions, and to the use thereof in methods of treating diabetes and hyperglycaemia.
  • Polypeptides have typically low solubilities in most non-aqueous solvents except certain aprotic solvents like dimethyl sulfoxide (DMSO), dimethylacetamide and dimethylformamide. However, the toxicity of these aprotic solvents disqualifies them from being used in pharmaceutical formulations to any significant degree.
  • aprotic solvents like dimethyl sulfoxide (DMSO), dimethylacetamide and dimethylformamide.
  • DMSO dimethyl sulfoxide
  • dimethylacetamide dimethylacetamide
  • dimethylformamide dimethylformamide
  • WO 00/42993 describes formulations for delivery of macromolecules, where the macromolecules are dissolved or dispersed in a low toxicity organic solvent which can be aerosolized for delivery to a patient's lung by inhalation.
  • organic polar protic solvents tend to destabilize polypeptides such as insulinotropic peptides due to partial unfolding of the polypeptides, which often enhances aggregation and chemical degradation processes significantly due to higher conformational flexibility.
  • Some organic polar protic solvents like ethanol might even act as a denaturant for polypeptides.
  • the organic polar protic solvents often contain small amounts of highly reactive impurities such as aldehydes and ketones, which compromises the stability of the polypeptide. Hence, it is difficult to formulate a non-aqueous solution of an insulinotropic peptide with adequate shelf life stability.
  • non-aqueous insulinotropic peptide solutions can be further processed into solution pressurized metered dose inhalers (pMDI), where the polar non-aqueous act as a co-solvent in order for the insulinotropic peptide to be solubilized in a hydrofluoroalkane they can be advantageously used for pulmonal administration.
  • pMDI solution pressurized metered dose inhalers
  • the non-aqueous insulinotropic peptide solutions can also be processed into microemulsions for oral administration by adding detergents and non-polar hydrophobic solvents such as oils.
  • the microemulsion might protect the insulinotropic peptide against proteolytic degradation and enhance the systemic absorption of the insulinotropic peptide from the gastrointestinal tract. Furthermore, it is anticipated that hydrolysis of the insulinotropic peptides is minimized in non-aqueous formulations due to lower water activity.
  • shelf life of liquid parenteral formulations of peptides must be at least a year, preferably longer.
  • the in-use period where the product may be transported and shaken daily at ambient temperature preferably should be several weeks.
  • a pharmaceutical non-aqueous composition comprising a dehydrated insulinotropic peptide, and at least one semi-polar protic organic solvent which insulinotropic peptide has been dehydrated at a target pH which is at least 1 pH unit from the pi of the insulinotropic peptide in aqueous solution, is provided.
  • a pharmaceutical non-aqueous composition comprising a dehydrated insulinotropic peptide, and at least one semi-polar protic organic solvent which insulinotropic peptide has been dehydrated at a target pH which is at least 1 pH unit from the pi of the insulinotropic peptide in aqueous solution, and where said target pH is in the range from about 6.0 to about 9.0, is provided.
  • insulinotropic peptides such as GLP-I in solid state (dehydrated) can be solubilized to a very high degree in a non-aqueous semi-polar protic solvent by optimizing the pH of said insulinotropic peptides in an aqueous solution before dehydration making the formulation of shelf-stable pharmaceutical formulations possible.
  • Such pharmaceutical compositions for e.g. oral, pulmonal and nasal use show high chemical and/or physical stability.
  • Compositions according to the invention such as oral pharmaceutical compositions using propylene glycol as a semi-polar protic organic solvent may also show significantly improved bioavailability.
  • a pharmaceutical non-aqueous composition comprising a dehydrated insulinotropic peptide, and at least one semi-polar protic organic solvent which insulinotropic peptide has been dehydrated at a target pH which is at least 1 pH unit from the pi of the insulinotropic peptide in aqueous solution, is provided.
  • a pharmaceutical non-aqueous composition comprising
  • a pharmaceutical non-aqueous composition comprising a mixture of
  • non-aqueous refers to a composition which comprises less than 10% w/w water.
  • the composition according to the invention comprises less than 8% w/w water, in a more preferred embodiment less than 5% w/w water, in a more preferred embodiment less than 3% w/w water and in an even more preferred embodiment less than 2% w/w water.
  • the term "dehydrated” as used herein in connection with a insulinotropic peptide refers to a insulinotropic peptide which has been dried from an aqueous solution.
  • target pH refers to the aqueous pH which will establish when dehydrated insulinotropic peptide is rehydrated in pure water to a concentration of approximately 40 mg/ml or more.
  • the target pH will typically be identical to the pH of the aqueous insulinotropic peptide solution from which the insulinotropic peptide was recovered by drying.
  • the pH of the insulinotropic peptide solution will not be identical to the target pH, if the insulinotropic peptide solution contains volatile acids or bases. It has been found that the pH history of the insulinotropic peptide will be determinant for the amount of the insulinotropic peptide, which can be solubilized in the semi-polar protic organic solvent.
  • the insulinotropic peptide has been dehydrated at a target pH which is at least 1 pH unit from the pi of the insulinotropic peptide in aqueous solution.
  • the target pH is more than 1 pH unit above the isoelectric point of the insulinotropic peptide.
  • the target pH is more than 1 pH unit below the isoelectric point of the insulinotropic peptide.
  • the target pH is more than 1.5 pH units above or below the pi of the insulinotropic peptide.
  • the target pH is 2.0 pH units above or below the pi of the insulinotropic peptide.
  • the target pH is 2.5 pH units above or below the pi of the insulinotropic peptide.
  • the target pH is above the pi of the insulinotropic peptide.
  • volatile base is meant a base, which to some extend will evaporate upon heating and/or at reduced pressure, e.g. bases which have a vapour pressure above 65 Pa at room temperature or an aqueous azeotropic mixture including a base having a vapour pressure above 65 Pa at room temperature.
  • volatile bases are ammonium hydroxides, tetraalkylammonium hydroxides, secondary amines, tertiary amines, aryl amines, alphatic amines or ammonium bicarbonate or a combination.
  • the volatile base can be bicarbonate, carbonate, ammonia, hydrazine or an organic base such as a lower aliphatic amines e.g. trimethyl amine, triethylamine, diethanolamines, triethanolamine and their salts.
  • the volatile base can be ammonium hydroxide, ethyl amine or methyl amine or a combination hereof.
  • volatile acid is meant an acid, which to some extend will evaporate upon heating and/or at reduced pressure, e.g. acids which have a vapour pressure above 65 Pa at room temperature or an aqueous azeotropic mixture including an acid having a vapour pressure above 65 Pa at room temperature.
  • volatile acids are carbonic acid, formic acid, acetic acid, propionic acid and butyric acid.
  • a “non volatile base” as mentioned herein means a base, which do not evaporate or only partly evaporate upon heating, e.g. bases with a vapour pressure below 65 Pa at room temperature.
  • the non volatile base can be selected from the group consisting of alkaline metal salts, alkaline metal hydroxides, alkaline earth metal salts, alkaline earth metal hydroxides and amino acids or a combination hereof.
  • Examples of non-volatile bases are sodium hydroxide, potassium hydroxide, calcium hydroxide, and calcium oxide.
  • non volatile acid as mentioned herein means an acid, which do not evaporate or only partly evaporate upon heating, e.g. bases with a vapour pressure below 65 Pa at room temperature.
  • non-volatile acids are hydrochloric acid, phosphoric acid and sulfuric acid.
  • the pi of the insulinotropic peptide refers to the isoelectric point of a insulinotropic peptide.
  • isoelectric point means the pH value where the overall net charge of a macromolecule such as a peptide is zero. In peptides there may be several charged groups, and at the isoelectric point the sum of all these charges is zero. At a pH above the isoelectric point the overall net charge of the peptide will be negative, whereas at pH values below the isoelectric point the overall net charge of the peptide will be positive.
  • the pi of a protein can be determined experimentally by electrophoresis techniques such as electrofocusing :
  • a pH gradient is established in an anticonvective medium, such as a polyacrylamide gel.
  • an anticonvective medium such as a polyacrylamide gel.
  • a protein When a protein is introduced in to the system it will migrate under influence of an electric field applied across the gel. Positive charged proteins will migrate to the cathode. Eventually, the migrating protein reaches a point in the pH gradient where its net electrical charge is zero and is said to be focused. This is the isoelectric pH (pi) of the protein.
  • the protein is then fixed on the gel and stained. The pi of the protein can then be determined by comparison of the position of the protein on the gel relative to marker molecules with known pi values.
  • the net charge of a protein at a given pH value can be estimated theoretically per a person skilled in the art by conventional methods.
  • the net charge of protein is the equivalent to the sum of the fractional charges of the charged amino acids in the protein : aspartate ( ⁇ -carboxyl group), glutamate ( ⁇ -carboxyl group), cysteine (thiol group), tyrosine (phenol group), histidine (imidazole side chains), lysine ( ⁇ -ammonium group) and arginine (guanidinium group).
  • aspartate ⁇ -carboxyl group
  • glutamate ⁇ -carboxyl group
  • cysteine thiol group
  • tyrosine phenol group
  • histidine imidazole side chains
  • lysine ⁇ -ammonium group
  • arginine guanidinium group
  • the drying i.e. dehydration of the insulinotropic peptide can be performed by any conventional drying method such e.g. by spray- , freeze-, vacuum-, open - and contact drying.
  • the insulinotropic peptide solution is spray dried to obtain a water content below about 10%.
  • the water content may be below about 8%, below about 6%, below about 5%, below about 4%, below about 3%, below about 2% or below about 1% calculated on/measured by loss on drying test (gravimetric) as stated in the experimental part.
  • the insulinotropic peptide is spray dried. In a further aspect of the invention, the insulinotropic peptide is freeze-dried.
  • the solubility obtained by the pre-treatment of the insulinotropic peptide by dehydration at the selected target pH in an organic solvent is at least 20 mg/ml. In a further aspect, the solubility of dehydrated insulinotropic peptide in the organic solvent is at least 30 mg/ml. In yet a further aspect, the solubility of dehydrated insulinotropic peptide in the organic solvent is at least 40 mg/ml. In yet a further aspect, the solubility of dehydrated insulinotropic peptide in the organic solvent is at least 50 mg/ml. In yet a further aspect, the solubility of dehydrated insulinotropic peptide in the organic solvent is at least 60 mg/ml.
  • the solubility of dehydrated insulinotropic peptide in the organic solvent is at least 70 mg/ml. In yet a further aspect, the solubility of dehydrated insulinotropic peptide in the organic solvent is at least 80 mg/ml. In yet a further aspect, the solubility of dehydrated insulinotropic peptide in the organic solvent is at least 100 mg/ml.
  • si-polar protic organic solvent refers to a hydrophilic, water miscible carbon-containing solvent that contains an O-H or N-H bond, or mixtures thereof. The polarity is reflected in the dielectric constant or the dipole moment of a solvent.
  • polar solvents dissolve polar compounds best and non-polar solvents dissolve non-polar compounds best: "like dissolves like”.
  • Strongly polar compounds like inorganic salts e.g. sodium chloride
  • Semi-polar solvents are here defined as solvents with a dielectricity constant in the range of 20-50, whereas polar and non-polar solvents are defined by a dielectricity constant above 50 and below 20, respectively. Examples of semi-polar protic are listed in Table 1 together with water as a reference.
  • 1,2-propanediol and propylene glycol is used interchangeable.
  • propanediol and glycerol is used interchangeably.
  • ethanediol and ethylene glycol is used interchangeably.
  • the solvent is selected from the group consisting of polyols.
  • polyol refers to chemical compounds containing multiple hydroxyl groups.
  • the solvent is selected from the group consisting of diols and triols.
  • diol refers to chemical compounds containing two hydroxyl groups.
  • triol refers to chemical compounds containing three hydroxyl groups.
  • the solvent is selected from the group consisting of glycerol (propanediol), ethanediol (ethylene glycol), 1,3-propanediol, methanol, 1,4- butanediol, 1,3-butanediol, propylene glycol (1,2-propanediol), ethanol and isopropanol, or mixtures thereof.
  • the solvent is selected from the group consisting of propylene glycol and glycerol.
  • the solvent is glycerol. This solvent is biocompatible at even high dosages and has a high solvent capacity for e.g. GLP-I compounds.
  • the solvent is selected from the group consisting of propylene glycol and ethylene glycol. These solvents have a low viscosity, are biocompatible at moderate doses, and have very high solvent capacity for e.g. GLP-I compounds.
  • the solvents should preferably be of high purity with a low content of e.g. aldehydes, ketones and other reducing impurities in order to minimize chemical deterioration of the solubilized insulinotropic peptide due to e.g. Maillard reaction.
  • Scavenger molecules like glycylglycine and ethylenediamine may be added to the formulations comprising semi- polar protic organic solvent(s) such as polyols to reduce deterioration of the insulinotropic peptide whereas antioxidants can be added to reduce the rate of formation of further reducing impurities.
  • the organic solvent is present in the pharmaceutical composition in an amount of at least 20% w/w. In a further aspect of the invention, the organic solvent is present in an amount of at least 30% w/w. In a further aspect of the invention, the organic solvent is present in an amount of at least 40% w/w. In a further aspect of the invention, the organic solvent is present in an amount of at least 50% w/w. In a further aspect of the invention, the organic solvent is present in an amount of at least 80% w/w.
  • the target pH advantageously is adjusted to between about 6.0 and about 9.0.
  • the target pH is between about 6.0 and about 9.0, such as between about 6.2 and about 8.4, between about 6.4 and about 8.7, between about 6.5 and about 8.5, between about 7.0 and about 8.5, or between about 7.2 and about 8.3.
  • the target pH is above about 7.4, above about 7.6, above about 7.8, above about 8.0, above about 8.2, above about 8.4 or above about 8.6. It is believed that the increased shelf stability is due to fewer tendencies of the insulinotropic peptides to fibrillate after having been dehydrated as described above.
  • shelf-stable pharmaceutical composition means a pharmaceutical composition which is stable for at least the period which is required by regulatory agencies in connection with therapeutic proteins.
  • a shelf-stable pharmaceutical composition is stable for at least one year at 5 0 C. Shelf-stability includes chemical stability as well as physical stability. Chemical instability involves degradation of covalent bonds, such as hydrolysis, racemization, oxidation or Crosslin king. Chemical stability of the formulations is evaluated by means of reverse phase (RP-HPLC) and size exclusion chromatography (SE-HPLC). In one aspect of the invention, the formation of peptide related impurities during shelf-life is less than 10 % of the total peptide content.
  • the formation of peptide related during impurities during shelf-life is less than 5 %.
  • the RP-HPLC analysis is typically conducted in water- acetonitrile or water-ethanol mixtures.
  • the solvent in the RP-HPLC step will comprise a salt such as Na 2 SO 4 , (NH 4 ) 2 SO 4 , NaCI, KCI, and buffer systems such as phosphate, and citrate and maleic acid.
  • the required concentration of salt in the solvent may be from about 0.1 M to about 1 M, preferable between 0.2 M to 0.5 M, most preferable between 0.3 to 0.4 M. Increase of the concentration of salt requires an increase in the concentration of organic solvent in order to achieve elution from the column within a suitable time.
  • Physical instability involves conformational changes relative to the native structure, which includes loss of higher order structure, aggregation, fibrillation, precipitation or adsorption to surfaces.
  • GLP-I compounds are known to be prone to instability due to fibrillation.
  • Physical stability of the formulations may be evaluated by conventional means of e.g. visual inspection, nephelometry and Thioflavin T assay after storage of the formulation at different temperatures for various time periods.
  • Conformational stability can be evaluated by circular dichroism and NMR as described by e.g. Hudson and Andersen, Peptide Science, vol 76 (4), pp. 298-308 (2004).
  • therapeutically active insulinotropic peptide or “therapeutic insulinotropic peptides” as used herein refers to an insulinotropic peptide able to cure, alleviate or partially arrest the clinical manifestations of a given disease and its complications.
  • therapeutically active insulinotropic peptide or “therapeutic insulinotropic peptides” as used herein means a insulinotropic peptide which is being developed for therapeutic use, or which has been developed for therapeutic use.
  • Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix, which is all within the ordinary skills of a trained physician or veterinary.
  • polypeptide or "peptide” is used interchangeably herein to mean a compound composed of at least five constituent amino acids connected by peptide bonds.
  • the constituent amino acids may be from the group of the amino acids encoded by the genetic code and they may be natural amino acids which are not encoded by the genetic code, as well as synthetic amino acids.
  • Natural amino acids which are not encoded by the genetic code are e.g. hydroxyproline, ⁇ -carboxyglutamate, ornithine, phosphoserine, D- alanine and D-glutamine.
  • Synthetic amino acids comprise amino acids manufactured by chemical synthesis, i.e.
  • D-isomers of the amino acids encoded by the genetic code such as D-alanine and D-leucine, Aib ( ⁇ -aminoisobutyric acid), Abu ( ⁇ -aminobutyric acid), Tie (tert-butylglycine), ⁇ -alanine, 3-aminomethyl benzoic acid, anthranilic acid.
  • polypeptides and peptides are well known in the art.
  • Polypeptides or peptides may for instance be produced by classical peptide synthesis, e.g. solid phase peptide synthesis using t-Boc or Fmoc chemistry or other well established techniques, see e.g. Greene and Wuts, "Protective Groups in Organic Synthesis", John Wiley & Sons, 1999.
  • the polypeptides or peptides may also be produced by a method which comprises culturing a host cell containing a DNA sequence encoding the (poly)peptide and capable of expressing the (poly)peptide in a suitable nutrient medium under conditions permitting the expression of the peptide.
  • the recombinant cell should be modified such that the non-natural amino acids are incorporated into the (poly)peptide, for instance by use of tRNA mutants.
  • pharmaceutical composition means a product comprising a therapeutically active insulinotropic peptide together with pharmaceutical excipients such as, a surfactant, buffer, preservative and tonicity modifier, said pharmaceutical composition being useful for treating, preventing or reducing the severity of a disease or disorder by administration of said pharmaceutical composition to a person.
  • a pharmaceutical composition is also known in the art as a pharmaceutical formulation. It is to be understood that pH of a pharmaceutical composition which is to be reconstituted is the pH value which is measured on the reconstituted composition produced by reconstitution in the prescribed reconstitution liquid at room temperature.
  • pharmaceutically acceptable means suited for normal pharmaceutical applications, i.e. giving rise to no serious adverse events in patients etc.
  • buffer refers to a chemical compound in a pharmaceutical composition that reduces the tendency of pH of the composition to change over time as would otherwise occur due to chemical reactions. Buffers include chemicals such as sodium phosphate, TRIS, glycine and sodium citrate.
  • preservative refers to a chemical compound which is added to a pharmaceutical composition to prevent or delay microbial activity (growth and metabolism).
  • examples of pharmaceutically acceptable preservatives are phenol, m- cresol and a mixture of phenol and m-cresol.
  • stabilizer refers to chemicals added to peptide containing pharmaceutical compositions in order to stabilize the peptide, i.e. to increase the shelf life and/or in-use time of such compositions.
  • stabilizers used in pharmaceutical formulations are L-glycine, L-histidine, arginine, glycylglycine, ethylenediamine, citrate, EDTA, polyethylene glycol, carboxymethylcellulose, and surfactants and antioxidants like alfa-tocopherol and l-ascorbic acid.
  • surfactant refers to any substance, in particular a detergent, that can adsorb at surfaces and interfaces, like liquid to air, liquid to liquid, liquid to container or liquid to any solid.
  • the surfactant may be selected from a detergent, such as ethoxylated castor oil, polyglycolyzed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, polysorbate, such as polysorbate-20, poloxamers, such as poloxamer 188 and poloxamer 407, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene derivatives such as alkylated and alkoxylated derivatives (tweens, e.g.
  • Tween-20, or Tween-80 monoglycerides or ethoxylated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, glycerol, cholic acid or derivatives thereof, lecithins, alcohols and phospholipids, glycerophospholipids (lecithins, kephalins, phosphatidyl serine), glyceroglycolipids (galactopyransoide), sphingophospholipids (sphingomyelin), and sphingoglycolipids (ceramides, gangliosides), DSS (docusate sodium, CAS registry no [577-11-7]), docusate calcium, CAS registry no [128-49-4]), docusate potassium, CAS registry no [7491-09-0]), SDS (sodium dodecyl sulfate or sodium lauryl sulfate), dipalmitoyl phosphatidic acid, sodium caprylate,
  • N-alkyl-N,N-dimethylammonio-l-propanesulfonates 3-cholamido-l-propyldimethyl- ammonio-1-propanesulfonate
  • dodecylphosphocholine myristoyl lysophosphatidylcholine, hen egg lysolecithin
  • cationic surfactants quarternary ammonium bases
  • non-ionic surfactants e. g.
  • alkyl glucosides like dodecyl ⁇ -D-glucopyranoside, dodecyl ⁇ -D-maltoside, tetradecyl ⁇ -D- glucopyranoside, decyl ⁇ -D-maltoside, dodecyl ⁇ -D-maltoside, tetradecyl ⁇ -D-maltoside, hexadecyl ⁇ -D-maltoside, decyl ⁇ -D-maltotrioside, dodecyl ⁇ -D-maltotrioside, tetradecyl ⁇ -D-maltotrioside, hexadecyl ⁇ -D-maltotrioside, n-dodecyl-sucrose, n-decyl-sucrose, fatty alcohol ethoxylates (e.
  • polyoxyethylene alkyl ethers like octaethylene glycol mono tridecyl ether, octaethylene glycol mono dodecyl ether, octaethylene glycol mono tetradecyl ether), block copolymers as polyethyleneoxide/polypropyleneoxide block copolymers (Pluronics/Tetronics, Triton X-IOO) ethoxylated sorbitan alkanoates surfactants (e. g. Tween-40, Tween-80, Brij-35), fusidic acid derivatives (e.g.
  • sodium tauro-dihydrofusidate etc. long-chain fatty acids and salts thereof C6-C12 (eg. oleic acid and caprylic acid), acylcarnitines and derivatives, N ⁇ -acylated derivatives of lysine, arginine or histidine, or side-chain acylated derivatives of lysine or arginine, N ⁇ -acylated derivatives of dipeptides comprising any combination of lysine, arginine or histidine and a neutral or acidic amino acid, N ⁇ -acylated derivative of a tripeptide comprising any combination of a neutral amino acid and two charged amino acids, or the surfactant may be selected from the group of imidazoline derivatives, or mixtures thereof.
  • C6-C12 eg. oleic acid and caprylic acid
  • acylcarnitines and derivatives N ⁇ -acylated derivatives of lysine, arginine or his
  • treatment of a disease means the management and care of a patient having developed the disease, condition or disorder.
  • the purpose of treatment is to combat the disease, condition or disorder.
  • Treatment includes the administration of the active compounds to eliminate or control the disease, condition or disorder as well as to alleviate the symptoms or complications associated with the disease, condition or disorder, and prevention of the disease, condition or disorder.
  • prevention of a disease is defined as the management and care of an individual at risk of developing the disease prior to the clinical onset of the disease.
  • the purpose of prevention is to combat the development of the disease, condition or disorder, and includes the administration of the active compounds to prevent or delay the onset of the symptoms or complications and to prevent or delay the development of related diseases, conditions or disorders.
  • analogue as used herein referring to a peptide means a modified peptide wherein one or more amino acid residues of the peptide have been substituted by other amino acid residues and/or wherein one or more amino acid residues have been deleted from the peptide and/or wherein one or more amino acid residues have been added to the peptide. Such addition or deletion of amino acid residues can take place at the N- terminal of the peptide and/or at the C-terminal of the peptide. In one embodiment an analogue comprises less than 6 modifications (substitutions, deletions, additions) relative to the native peptide. In another embodiment an analogue comprises less than 5 modifications (substitutions, deletions, additions) relative to the native peptide.
  • an analogue comprises less than 4 modifications (substitutions, deletions, additions) relative to the native peptide. In another embodiment an analogue comprises less than 3 modifications (substitutions, deletions, additions) relative to the native peptide. In another embodiment an analogue comprises less than 2 modifications (substitutions, deletions, additions) relative to the native peptide. In another embodiment an analogue comprises only a single modification (substitutions, deletions, additions) relative to the native peptide.
  • the added and/or exchanged amino acid residues can either be codable amino acid residues or other naturally occurring residues or purely synthetic amino acid residues.
  • derivative as used herein in relation to a parent peptide means a chemically modified parent protein or an analogue thereof, wherein at least one substituent is not present in the parent protein or an analogue thereof, i.e. a parent protein which has been covalently modified.
  • Typical modifications are amides, carbohydrates, alkyl groups, acyl groups, esters, PEGylations and the like.
  • GLP-I GLP-1(7- 37) (SEQ ID NO. 1), insulinotropic analogue thereof and insulinotropic derivatives thereof.
  • GLP-I analogues are GLP-l(7-36) amide, Arg 34 -GLP- 1(7-37), Gly 8 -GLP-l(7-37), Val 8 -GLP-l(7-36)-amide and Val 8 Asp 22 -GLP-l(7-37).
  • Non- limiting examples of GLP-I derivatives are desamino-His 7 , Arg 26 , Lys 34 (N ⁇ -( ⁇ -Glu(N ⁇ - hexadecanoyl)))-GLP-l(7-37), desamino-His 7 , Arg 26 , Lys 34 (N ⁇ -octanoyl)-GLP-l(7-37), Arg 26 ' 34 , Lys 38 (N ⁇ -( ⁇ -carboxypentadecanoyl))-GLP-l(7-38), Arg 26 ' 34 , Lys 36 (N ⁇ -( ⁇ -Glu(N ⁇ - hexadecanoyl)))-GLP-l(7-36) and Arg 34 , Lys 26 (N ⁇ -( ⁇ -Glu(N ⁇ -hexadecanoyl)))-GLP-l(7-37).
  • dipeptidyl aminopeptidase IV protected means a compound, e.g. a GLP-I analogue, which is more resistant to dipeptidyl aminopeptidase IV (DPP-IV) than the native compound, e.g. GLP-l(7-37). Resistance of a GLP-I compound towards degradation by dipeptidyl aminopeptidase IV is determined by the following degradation assay:
  • One method for performing this analysis is: The mixtures are applied onto a Vydac C18 widepore (30 nm pores, 5 ⁇ m particles) 250 x 4.6 mm column and eluted at a flow rate of 1 ml/min with linear stepwise gradients of acetonitrile in 0.1% trifluoroacetic acid (0% acetonitrile for 3 min, 0-24% acetonitrile for 17 min, 24-48% acetonitrile for 1 min) according to Siegel et al., Regul. Pept. 1999;79:93-102 and Mentlein et al. Eur. J. Biochem. 1993;214:829-35.
  • Peptides and their degradation products may be monitored by their absorbance at 220 nm (peptide bonds) or 280 nm (aromatic amino acids), and are quantified by integration of their peak areas related to those of standards.
  • the rate of hydrolysis of a GLP-I compound by dipeptidyl aminopeptidase IV is estimated at incubation times which result in less than 10% of the GLP-I compound being hydrolysed.
  • insulinotropic as used herein referring to a peptide or a compound means the ability to stimulate secretion of insulin in response to an increased plasma glucose level. Insulinotropic peptides and compounds are agonists of the GLP-I receptor.
  • the insulinotropic property of a compound may be determined by in vitro or in vivo assays known in the art. The following in vitro assay may be used to determine the insulinotropic nature of a compound such as a peptide.
  • Preferably insulinotropic compounds exhibit an EC 50 value in below assay of less than 5 nM, even more preferably EC50 values less than 500 pM.
  • Baby hamster kidney (BHK) cells expressing the cloned human GLP-I receptor (BHK 467- 12A) are grown in DMEM media with the addition of 100 IU/mL penicillin, 100 ⁇ L/mL streptomycin, 10% foetal calf serum and 1 mg/mL Geneticin G-418 (Life Technologies).
  • Plasma membranes are prepared by homogenization in buffer (10 mM Tris-HCI, 30 mM NaCI and 1 mM dithiothreitol, pH 7.4, containing, in addition, 5 mg/mL leupeptin
  • the homogenate was centrifuged on top of a layer of 41% W7v sucrose. The white band between the two layers was diluted in buffer and centrifuged. Plasma membranes were stored at -80 0 C until used.
  • the functional receptor assay is carried out by measuring cAMP as a response to stimulation by the insulinotropic peptide or insulinotropic compound.
  • Incubations are carried out in 96-well microtiter plates in a total volume of 140 mL and with the following final concentrations: 50 mM Tris-HCI, 1 mM EGTA, 1.5 mM MgSO 4 , 1.7 mM ATP, 20 mM GTP, 2 mM 3-isobutyl-l-methylxanthine (IBMX), 0.01% w/v Tween-20, pH 7.4. Compounds are dissolved and diluted in buffer. GTP is freshly prepared for each experiment: 2.5 ⁇ g of membrane is added to each well and the mixture is incubated for 90 min at room temperature in the dark with shaking. The reaction is stopped by the addition of 25 mL 0.5 M HCI.
  • prodrug of an insulinotropic compound means a chemically modified compound which following administration to the patient is converted to an insulinotropic compound. Such prodrugs are typically amino acid extended versions or esters of an insulinotropic compound.
  • exendin-4 compound as used herein is defined as exendin-4(l-39) (SEQ ID NO. 2), insulinotropic fragments thereof, insulinotropic analogs thereof and insulinotropic derivatives thereof.
  • Insulinotropic fragments of exendin-4 are insulinotropic peptides for which the entire sequence can be found in the sequence of exendin-4 (SEQ ID NO. 2) and where at least one terminal amino acid has been deleted.
  • Examples of insulinotropic fragments of exendin-4(l-39) are exendin-4(l-38) and exendin-4(l-31).
  • the insulinotropic property of a compound may be determined by in vivo or in vitro assays well known in the art.
  • the compound may be administered to an animal and monitoring the insulin concentration over time.
  • Insulinotropic analogs of exendin-4(l-39) refer to the respective molecules wherein one or more of the amino acids residues have been exchanged with other amino acid residues and/or from which one or more amino acid residues have been deleted and/or from which one or more amino acid residues have been added with the proviso that said analogue either is insulinotropic or is a prodrug of an insulinotropic compound.
  • insulinotropic analog of exendin-4(l-39) is Ser 2 Asp 3 -exendin-4(l-39) wherein the amino acid residues in position 2 and 3 have been replaced with serine and aspartic acid, respectively (this particular analog also being known in the art as exendin-3).
  • Insulinotropic derivatives of exendin-4(l-39) and analogs thereof are what the person skilled in the art considers to be derivatives of these peptides, i.e. having at least one substituent which is not present in the parent peptide molecule with the proviso that said derivative either is insulinotropic or is a prodrug of an insulinotropic compound.
  • substituents are amides, carbohydrates, alkyl groups, esters and lipophilic substituents.
  • An example of an insulinotropic derivatives of exendin-4(l-39) and analogs thereof is Tyr 31 -exendin-4(l-31)-amide.
  • stable exendin-4 compound as used herein means a chemically modified exendin-4(l-39), i.e. an analogue or a derivative which exhibits an in vivo plasma elimination half-life of at least 10 hours in man, as determined by conventional methods.
  • dipeptidyl aminopeptidase IV protected exendin-4 compound as used herein means an exendin-4 compound which is more resistant towards the plasma peptidase dipeptidyl aminopeptidase IV (DPP-IV) than exendin-4 (SEQ ID NO. 2), as determined by the assay described under the definition of dipeptidyl aminopeptidase IV protected GLP-I compound.
  • the GLP-I analogues may be such wherein the naturally occurring Lys at position 34 of GLP-l(7-37) has been substituted with Arg. All amino acids for which the optical isomer is not stated is to be understood to mean the L-isomer.
  • an analogue of the insulinotropic peptide is obtained wherein a maximum of 17 amino acids have been modified relative to the unmodified insulinotropic peptide. In aspects of the invention a maximum of 15 amino acids have been modified. In aspects of the invention a maximum of 10 amino acids have been modified. In aspects of the invention a maximum of 8 amino acids have been modified. In aspects of the invention a maximum of 7 amino acids have been modified. In aspects of the invention a maximum of 6 amino acids have been modified. In aspects of the invention a maximum of 5 amino acids have been modified. In aspects of the invention a maximum of 4 amino acids have been modified. In aspects of the invention a maximum of 3 amino acids have been modified. In aspects of the invention a maximum of 2 amino acids have been modified. In aspects of the invention 1 amino acid has been modified.
  • the therapeutically active insulinotropic peptide is selected from the group consisting of insulinotropic peptide, GLP-l(7-37) or an analog or derivative thereof, exendin or an analog or derivative thereof and GLP-2 or an analog or derivative thereof.
  • the insulintropic polypeptide is a glucagon-like peptide.
  • the insulintropic polypeptide is selected from the group consisting of GLP-I, GLP-2, exendin-4, exendin-3 and analogues and derivatives thereof.
  • the glucagon-like peptide is an insulinotropic agent.
  • Conformational stability protein based drugs is important for maintaining biological activity and for minimizing irreversible loss of structure due to denaturation and fibrillation.
  • Especially large insulinotropic peptides and proteins are labile with respect to conformational change due to complicated refolding patterns.
  • insulinotropic peptides with a known history of fibrillation, such as GLP-I are particularly sensitive towards destabilization of tertiary structure (i.e. formation of a molten globular state).
  • Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject.
  • the pharmaceutical formulation comprises a therapeutically active insulinotropic peptide in a concentration from 0.1 % w/w to 50 % w/w.
  • Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject.
  • the present invention further provides a process for the preparation of a pharmaceutical solution by:
  • a target pH value which is 1 unit, preferably 2 units and more preferably 2.5 pH units above or below the pi of the insulinotropic peptide
  • the present invention further provides a process for the preparation of a pharmaceutical composition by:
  • adjusting the pH value to 1 unit, preferably 2 units and more preferably 2.5 pH units above or below the pi of the insulinotropic peptide e.g. by adding a non-volatile base or a acid, such as hydrochloric acid or sodium hydroxide, to the solution
  • the insulinotropic peptide is added to an aqueous solution.
  • the aqueous solution can be pure water or it can contain excipients or an alkaline solution.
  • the pH of the insulinotropic peptide solution is adjusted with an alkaline solution comprising a non-volatile base.
  • the non volatile base can be selected from the group consisting of alkaline metal salts, alkaline metal hydroxides, alkaline earth metal salts, alkaline earth metal hydroxides and amino acids or a combination hereof.
  • the pH can be adjusted with sodium hydroxide, potassium hydroxide, calcium hydroxide, calcium oxide or any combination hereof.
  • the pH of the insulinotropic peptide solution is adjusted with a non-volatile acid selected from hydrochloric acid, phosphoric acid and sulfuric acid.
  • the insulinotropic peptide non-aqueous solution comprises glycylglycine.
  • Glycylglycine might act as a scavenger for reductive impurities in the solvent such as e.g. glyceraldehyde.
  • glycylglycine is added to a propylene glycol solution comprising insulin e.g. in a concentration of glycylglycine in the solution of between about 4 mM and about 200 mM.
  • the insulinotropic peptide non-aqueous solution comprises Tween 80 and oleic acid.
  • Tween 80 and oleic acid When Tween 80 and oleic acid is added to a non-aqueous insulinotropic peptide solution, the insulinotropic peptide solution forms a microemulsion upon dilution with an aqueous liquid following oral administration.
  • the microemulsion might act as an absorption enhancer and furthermore generate more reproducible absorption kinetics.
  • the concentration of Tween 80 in the solution will e.g. be between about 30 and 70 % w/w and the concentration of oleic acid will e.g. be between 10 and 30 % w/w.
  • the invention is related to a pharmaceutical composition for the treatment of type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in patients in need of such a treatment.
  • the invention is related to a pharmaceutical composition according to the invention with a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable additive, which composition can be provided for the treatment of type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in patients in need of such a treatment.
  • a method of treating type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in a patient in need of such a treatment comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition according to the invention.
  • a method of treating type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in a patient in need of such a treatment comprising administering to the patient a therapeutically effective amount of an pharmaceutical composition according to the invention, optionally together with a pharmaceutically acceptable carrier and/or pharmaceutical acceptable additives.
  • a method for the manufacture of a pharmaceutical composition according to the invention for the use in the treatment of type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia.
  • a method for the manufacture of a pharmaceutical composition for the use in the treatment of type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia is provided.
  • compositions according to the invention can, for example, be administered subcutaneously, orally, nasally or pulmonary.
  • composition according to the invention is formulated analogously with the formulation of known therapeutically active insulinotropic peptides. Furthermore, for subcutaneous administration, the compositions according to the invention are administered analogously with the administration of known therapeutically active insulinotropic peptides and, generally, the physicians are familiar with this procedure.
  • the compositions according to the invention may be administered by inhalation in a dose effective manner to increase circulating insulin peptide levels and/or to lower circulating glucose levels.
  • Such administration can be effective for treating disorders such as diabetes or hyperglycaemia.
  • Achieving effective doses of e.g. insulinotropic peptides requires administration of an inhaled dose of a composition according to the invention comprising more than about 0.5 ⁇ g/kg to about 50 ⁇ g/kg insulinotropic peptide.
  • a therapeutically effective amount can be determined by a knowledgeable practitioner, who will take into account factors including insulin level, blood glucose levels, the physical condition of the patient, the patient's pulmonary status, or the like.
  • a composition according the invention may be delivered by inhalation to achieve rapid absorption of the therapeutically active insulinotropic peptide.
  • Administration by inhalation can result in pharmacokinetics comparable to subcutaneous administration of insulinotropic peptides.
  • Different inhalation devices typically provide similar pharmacokinetics when similar particle sizes and similar levels of lung deposition are compared.
  • a composition may be delivered by any of a variety of inhalation devices known in the art for administration of a therapeutic agent by inhalation. These devices include metered dose inhalers, nebulizers, dry powder generators, sprayers, and the like.
  • a composition of this invention is in one aspect delivered by a pressurized metered dose inhaler or a sprayer.
  • an inhalation device for administering a composition according to the invention is advantageously reliable, reproducible, and accurate.
  • the inhalation device should deliver small particles, for example particles less than about 10 ⁇ m, for example about 1-5 ⁇ m, for good respirability.
  • Some specific examples of commercially available inhalation devices suitable for the practice of this invention are TurbohalerTM (Astra), Rotahaler ® (Glaxo), Diskus ® (Glaxo), SpirosTM inhaler (Dura), devices marketed by Nektar, 3M Drug Delivery Systems and Bespak, AERxTM (Aradigm), the Ultravent ® nebulizer (Mallinckrodt), the Acorn II ® nebulizer (Marquest Medical Products), the Ventolin ® metered dose inhaler (Glaxo), the Spinhaler ® powder inhaler (Fisons), or the like.
  • pMDIs Pressurised metered dose inhalers
  • pMDIs comprise a pressure resistant aerosol canister typically filled with a product such as a drug dissolved in a liquefied propellant (solution formulations) or micronized particles suspended in a liquefied propellant (suspension formulations) where the container is fitted with a metering valve.
  • solution formulations offer the advantage of being homogeneous with the active ingredient and excipients completely dissolved in the propellant vehicle or its mixture with suitable co-solvents such as ethanol. Solution formulations also obviate physical stability problems associated with suspension formulations so assuring more consistent uniform dosage administration.
  • Hydrofluoroalkanes and in particular 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) and their mixtures have been acknowledged to be the best candidates for non-CFC propellants.
  • Actuation of the metering valve allows a small portion of the spray product to be released whereby the pressure of the liquefied propellant carries the dissolved or micronized drug particles out of the container to the patient.
  • the valve actuator is used to direct the aerosol spray into the patient's oropharynx.
  • the canisters may consist of aluminium or stainless steel having the internal surface coated with an inert organic coating, fitted with a metering valve having a 63 microliter metering chamber provided with a butyl rubber gasket as described in WO 03/078538.
  • the formulation of the invention depends on the type of inhalation device employed.
  • the frequency of administration and length of time for which the system is activated will depend mainly on the concentration of therapeutic insulinotropic peptide in the aerosol.
  • shorter periods of administration can be used at higher concentrations of therapeutic insulinotropic peptide in the nebulizer solution.
  • Devices such as metered dose inhalers can produce higher aerosol concentrations, and can be operated for shorter periods to deliver the desired amount of insulinotropic peptide.
  • Devices such as powder inhalers deliver active agent until a given charge of agent is expelled from the device. In this type of inhaler, the amount of composition according to the invention in a given quantity of the powder determines the dose delivered in a single administration.
  • the particle size of an insulinotropic peptide in the formulation delivered by the inhalation device is critical with respect to the ability of the peptide to make it into the lungs, and into the lower airways or alveoli.
  • the insulinotropic peptide in the composition of this invention can be formulated so that at least about 10% of the insulinotropic peptide delivered is deposited in the lung, for example about 10 to about 20%, or more. It is known that the maximum efficiency of pulmonary deposition for mouth breathing humans is obtained with particle sizes of about 2 ⁇ m to about 3 ⁇ m. Pulmonary deposition decreases substantially when particle sizes are above about 5 ⁇ m. Particle sizes below about 1 ⁇ m cause pulmonary deposition to decrease, and it becomes difficult to deliver particles with sufficient mass to be therapeutically effective.
  • particles of insulinotropic peptide delivered by inhalation have a particle size less than about 10 ⁇ m, for example in the range of about 1 ⁇ m to about 5 ⁇ m.
  • the formulation of insulinotropic peptide is selected to yield the desired particle size in the chosen inhalation device.
  • the insulinotropic peptide solution may optionally be combined with pharmaceutical carriers or excipients which are suitable for respiratory and pulmonary administration.
  • Such carriers may serve simply as bulking agents when it is desired to reduce the therapeutic insulinotropic peptide such as insulin concentration in the liquid which is being delivered to a patient, but may also serve to enhance the stability of the compositions.
  • Suitable materials include carbohydrates, e.g., (a) monosaccharides such as fructose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, trehalose, cellobiose, and the like; cyclodextrins, such as 2-hydroxypropyl--cyclodextrin; and polysaccharides, such as raffinose, maltodextrins, dextrans, and the like; (b) amino acids, such as glycine, arginine, aspartic acid, glutamic acid, cysteine, lysine, histidine, arginine and the like; (c) organic salts prepared from organic acids and bases, such as sodium citrate, sodium ascorbate, magnesium gluconate, sodium gluconate, tromethamine hydrochloride, and the like; (d) peptides and proteins, such as aspartame, human serum album
  • Such carrier materials may be combined with the therapeutic insulinotropic peptide such as insulin peptide prior to dehydration such as spray drying, i.e., by adding the carrier material to the insulinotropic peptide solution which is prepared for spray drying. In that way, the carrier material will be formed simultaneously with and as part of the protein particles.
  • the insulinotropic peptide when the carrier is formed by spray drying together with the insulinotropic peptide, the insulinotropic peptide will be present in each individual particle at a weight percent in the range from 5% to 95%, preferably from 20% to 80%.
  • the remainder of the particle will primarily be carrier material (typically being from 5% to 95%, usually being from 20% to 80% by weight), but will also include buffer (s) may include other components as described above.
  • Non-aqueous insulinotropic peptide formulations may also be combined with other active components.
  • Amylin is a hormone which is secreted with insulin from the pancreatic 0-cells in normal (non-diabetic) individuals. It is believed that amylin modulates insulin activity in vivo, and it has been proposed that simultaneous administration of amylin with insulin could improve blood glucose control. Combining amylin with insulin in the compositions of the present invention will provide a particularly convenient product for achieving such simultaneous administration.
  • Amylin may be combined with insulin at from 0.1% by weight to 10% by weight (based on the total weight of insulin in a dose), preferably from 0.5% by weight to 2.5% by weight.
  • Amylin is available from commercial suppliers, such as Amylin Corporation, San Diego, California, and can be readily formulated in the compositions of the present invention.
  • amylin may be dissolved in aqueous or other suitable solutions together with the insulin, and optionally carriers, and the solution spray dried to produce the powder product.
  • a spray including the spray-dried insulinotropic peptide can be produced by forcing a suspension or solution of insulinotropic peptide through a nozzle under pressure.
  • the nozzle size and configuration, the applied pressure, and the liquid feed rate can be chosen to achieve the desired output and particle size.
  • An electrospray can be produced, for example, by an electric field in connection with a capillary or nozzle feed.
  • particles of e.g. insulin delivered by a sprayer have a particle size less than about 10 ⁇ m, for example in the range of about 1 ⁇ m to about 5 ⁇ m.
  • compositions according to the present invention containing a dehydrated such as spray-dried insulinotropic peptide dissolved in a semi-polar protic organic solvent such as in a polyol may also be administered parenterally to patients in need of such a treatment.
  • Parenteral administration may be performed by subcutaneous, intramuscular or intravenous injection by means of a syringe, optionally a pen-like syringe.
  • parenteral administration can be performed by means of an infusion pump.
  • the preparations of the invention may be used in connection with pumps such as insulin pumps.
  • the insulin pumps may be prefixed and disposable, or the insulin preparations may be supplied from a reservoir which is removable. Insulin pumps may be skinmounted, implanted or carried, and the path of the insulin preparation from the storage compartment of the pump to the patient may be more or less tortuous.
  • Non- limiting examples of insulin pumps are disclosed in US 5,957,895, US 5, 858, 001, US4., 468, 221, US 4,468, 221, US 5, 957, 895, US 5,858, 001, US6,074,US US5, 858, 001, US 5,527,288, and US 6, 074, 369.
  • compositions according to the present invention of the dehydrated such as spray-dried insulinotropic peptide can be prepared using the conventional techniques of the pharmaceutical industry which involve dissolving and mixing the ingredients in a semi-polar protic organic solvent such as a polyol as appropriate to give the desired end product.
  • injection is the typical mode of administering a biologically active protein to the systemic circulation.
  • the recipient may experience discomfort or pain by injection. For this reason and others there may be problems with patient compliance using injection as a mode of administration.
  • One alternative to injection is the peroral administration of biologically active insulinotropic peptides.
  • oral delivery may have advantages beyond convenience and compliance issues. Insulin absorbed in the gastrointestinal tract mimics the physiology of insulin secreted by the pancreas because both are released into the portal vein and carried directly to the liver. Absorption into the portal circulation maintains a peripheral-portal insulin gradient that regulates insulin secretion.
  • insulinotropic peptides are extremely low due to extensive proteolytic degradation in the gastrointestinal tract and low epithelial permeability.
  • stabilization of insulinotropic peptides against proteolytic degradation by protein engineering, such as pegylation and mutation of hot spots is a commonly used strategy to improve oral bioavailability.
  • Another strategy to reduce proteolytic degradation is to incorporate the insulinotropic peptide into nanoparticles, microparticles, microemulsions, microemulsion pre-concentrates, liposomes and the like.
  • the drug is not only protected from the hostile environment in the stomach and gastrointestinal tract but also these particles might be taken up from the enteral route into the systemic circulation via the Peyers patches.
  • the pharmaceutical non-aqueous composition is a microemulsion pre-concentrate.
  • This is a composition which spontaneously self emulsifies upon dilution with an aqueous medium, e.g. water or gastrointestinal juice into for example an oil-in- water (o/w) microemulsion.
  • Microemulsions are being understood as being thermodynamically stable systems with a mean domain size of the emulsified phase in the lower nm range, for example between 20-400 nm.
  • the microemulsion pre-concentrate comprises one or more hydrophilic components, one or more lipophilic components, one or more non-ionic surfactants and/or co-surfactants and an active ingredient e.g.
  • microemulsion pre- concentrate may, if appropriate, comprise conventional adjuvants and additives. These self (micro)-emulsifying pre-concentrates can be ingested with the expectation that a microemulsion forms in the gastrointestinal tract.
  • the microemulsion pre- concentrate may be administered encapsulated in an enteric coated soft gelatine capsule. Many microemulsions have been reported to enhance the bioavailability of several therapeutic compounds after oral administration.
  • composition of a microemulsion pre-concentrate is: a) at least one semi-polar protic organic solvent such as a polyol (e.g. propylene glycol and/or glycerol) b) one or more hydrophilic components such as glycerol and/or propylene glycol b) one or more lipophilic components such as oils (e.g. mono-diglycerides and/or triglycerides) c) one or more non-ionic surfactants such as poloxamers and/or polysorbates d) one or more co-surfactants such as ethanol e) a dehydrated therapeutically active insulinotropic peptide (e.g. GLPl) f) one or more additives such as antioxidants and/or stabilizers.
  • a semi-polar protic organic solvent such as a polyol (e.g. propylene glycol and/or glycerol)
  • hydrophilic components such as glycerol and/or propylene glycol
  • compositions according to the present invention containing a dehydrated such as a spray-dried insulinotropic peptide dissolved in a semi-polar protic organic solvent such as in a polyol may also be administered bucally or sublingually in the form of aerosolised spray to patients in need of such a treatment.
  • a dehydrated such as a spray-dried insulinotropic peptide dissolved in a semi-polar protic organic solvent such as in a polyol
  • a semi-polar protic organic solvent such as in a polyol
  • the Oral-lynTM formulation developed by Generex Biotechnology Corporation is an example of a buccal aerosol formulation administered via a pressurized metered dose inhaler (pMDI).
  • Hydrofluoroalkanes (HFA) such as HFA 134a and 227, are typically used as propellants. Insulinotropic peptides are typically highly soluble in water at pH values more than 1 unit below or above pi.
  • Solution-type metered dose inhalers are generally preferred relative to suspension-type pMDI, which tend to have a higher variation in dose uniformity due to creaming or sedimentation of particles.
  • the solution type pMDI may be formulated with stabilisers and other additives, such as permeation enhancers in addition to the insulinotropic peptide.
  • the insulinotropic peptide may alternatively be administered buccally or sublingually as a pumpable, such as the Coro Nitro Pump Spray® for sublingual administration of nitroglycerin.
  • the oral spray aerosol should preferably have droplet diameters larger than 10 ⁇ m.
  • Mucoadhesive drug delivery systems have gained large interest in non-invasive protein/peptide delivery. They may increase the residence time of the delivery system on mucosal tissues. Several bioadhesive delivery systems have been reported to enhance the bioavailability of proteins and peptides for example after oral administration.
  • a non-aqueous free bioadhesive composition comprises a active protein or peptide, at least one bioadhesive polymer, and one or more semi-polar protic organic solvent such as a polyol(s).
  • the composition may, if appropriate, comprise conventional adjuvants and additives.
  • the bioadhesive polymer may for example be poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymers (such as Poloxamers), polyvinylpyrrolidone (such as Povidone or PVP), polyacrylic acid, polycarbophil (such as Carbopol or Carbomer), chitosan, all kinds of thiolated polymers (such as Thiomers), cellulose, alginates, hydroxyethylcellulose or other bioadhesive polymers.
  • poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymers such as Poloxamers
  • polyvinylpyrrolidone such as Povidone or PVP
  • polyacrylic acid such as polycarbophil (such as Carbopol or Carbomer)
  • chitosan all kinds of thiolated polymers (such as Thiomers)
  • cellulose alginates
  • the composition can be a liquid, semi-solid or a solid dosage form.
  • compositions would have the advantage compared to for example conventional bioadhesive hydrogels, that the required aqueous medium in these formulations can be avoided and thereof increased storage stability as well as increased bioavailabilty (triggered by the polyol) will be achieved.
  • bioadhesive composition a) a dehydrated therapeutically active insulinotropic peptide (e.g. GLPl) b) at least one semi-polar protic organic solvent such a polyol (e.g. propylene glycol and/or glycerol) c) bioadhesive polymer (e.g. Povidone and/or Poloxamer) d)
  • a dehydrated therapeutically active insulinotropic peptide e.g. GLPl
  • semi-polar protic organic solvent such as a polyol (e.g. propylene glycol and/or glycerol)
  • bioadhesive polymer e.g. Povidone and/or Poloxamer
  • a non-aqueous composition contains a combination of a dehydrated therapeutically active insulinotropic peptide, at least one semi-polar protic organic solvent such as polyol and one or more conventional permeation enhancers.
  • permeation enhancers are but not limited to fatty acids, palmitoyl carnitine chloride, ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), EDTA, bile salts, ionic- as well as non-ionic surfactants such as phospholipids and alkylglycosides, polymers, chitosan, citric acid and sodium salicylate.
  • the composition may, if appropriate, comprise conventional adjuvants and additives.
  • compositions of the present invention can be administered in a format selected from e.g. a tablet, a capsule, a suppository, a liquid, a spray or an aerosol for buccal and peroral administration.
  • solid dosage forms based on semi-polar protic organic solvent(s) such as polyols comprises at least one polyol and one or more at room temperature solid excipients for example a poloxamer, PEG or PEG stearate.
  • the composition contains a dehydrated therapeutically active insulinotropic peptide, at least one semi-polar protic organic solvent such as at least one polyol, and at least one at room temperature solid non ionic excipient for example poloxamers or polyoxyethylene glycols or a mixture of solid excipients.
  • solid poloxamers are Pluronic F-127, Pluronic F-68.
  • solid PEGs are PEG 3350, PEG 4000, PEG 8000.
  • the solid composition may, if appropriate, comprise conventional adjuvants and additives such as binders, glidants and lubricants to ensure efficient tabletting; and disintegrants to ensure that the tablet breaks up in the digestive tract.
  • Tablets and capsules may be coated with a entero coating, which ruptures or becomes permeable upon contacting an aqueous environment of a defined pH, make it possible for contents of the dosage format to be selectively released at a desired site in the gastrointestinal tract (e.g. small and large intestine) by selecting the a suitable pH-soluble polymer for a specific region.
  • a entero coating which ruptures or becomes permeable upon contacting an aqueous environment of a defined pH, make it possible for contents of the dosage format to be selectively released at a desired site in the gastrointestinal tract (e.g. small and large intestine) by selecting the a suitable pH-soluble polymer for a specific region.
  • enteric polymers include but are not limited to cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, polyvinylacetate phthalate, hydroxypropylmethylcellulose phthalate, methacrylic acid copolymer, shellac, methylcellulose phthalate, cellulose acetate trimellitate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate succinate, cellulose acetate malate, cellulose benzoate phthalate, cellulose propionate phthalate, carboxymethylethylcellulose, ethyl hydroxyethylcel Iu lose phthalate, shellac, styrene- acrylic acid copolymer, methyl acrylate-acrylic acid copolymer, methyl acrylate- methacrylic acid copolymer, butyl acrylate-styrene-acrylic acid copolymer, methacrylic acid-methyl methacrylate copolymer, methacryl
  • the dosage form is soft gelatine capsule containing a liquid.
  • composition comprising a mixture of
  • insulinotropic peptide has been dehydrated at a target pH which is at least 1 pH unit from the pi of the insulinotropic peptide in aqueous solution, and where said target pH preferably is in the range from about 6.0 to about 9.0.
  • composition according to any one of embodiments 1-24, which comprises less than 10% w/w water.
  • composition according to any one of embodiments 1-27, wherein the composition is for pulmonary, parenteral, nasal or oral treatment of diabetes or hyperglycaemia.
  • composition according to any one of embodiments 1-27, wherein the composition is for pulmonary treatment of diabetes or hyperglycaemia.
  • composition according to any one of embodiments 1-27, wherein the composition is for oral treatment of diabetes or hyperglycaemia.
  • composition according to any one of embodiments 1-30, wherein the insulinotropic peptide is selected from the group consisting of GLP-I, GLP-2, Exendin- 3, Exendin-4 and analogues and derivatives thereof.
  • said insulinotropic peptide comprises a lipophilic substituent selected from the group consisting of CH 3 (CH 2 ) n CO- wherein n is 4 to 38, and HOOC(CH 2 ) m CO- wherein m is from 4 to 38.
  • insulinotropic peptide is acylated GLP-I or an acylated GLP-I analogue.
  • GLP-I analogue is selected from the group consisting of: GLP-l(7-37); Arg34-GLP-l(7-37); Aib8,Arg34-GLP-l(7-37); Aib8,Aib22,Arg34-GLP-l(7-37); Arg34-GLP-l(7-37); [3-(4- Imidazolyl)propionyl7,Arg34]GLP-l-(7-37); Gly8,Arg34-GLP-l(7-37); Aib8,Arg34,Pro37- GLP-l(7-37); Aib8,Aib22,Aib27,Aib30,Arg34,Aib35,Pro37- GLP-I (7-37)amide; Arg26,Lys38-GLP-l(7-38); Arg26,Arg34,Lys38-GLP-l(7-38); Arg26,Arg34,Lys38-GLP-l(7-38);
  • insulinotropic peptide is selected from the group consisting of: N-epsilon26--(17-carboxyheptadecanoyl)-[Aib8,Arg34]GLP-l-(7-37)-peptide,
  • N-epsilon37 Polyethyleneglycol2000[DesaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-l
  • N-epsilon37 (3-((2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-Hexadecyloxyethoxy)ethoxy)ethoxy)) propionyl) [DesaminoHis7,Glu22,Arg26,Arg34,l_ys37]GLP-l(7-37)-amide,
  • insulinotropic peptide is Arg34, Lys26(N ⁇ -( ⁇ -Glu(N ⁇ -hexadecanoyl)))-GLP-l(7-37).
  • composition according to any one of the preceding embodiments, wherein the concentration of said insulinotropic peptide is in the range from about 0.1 mg/ml to about 25 mg/ml, in the range from about 1 mg/ml to about 25 mg/ml, in the range from about 2 mg/ml to about 15 mg/ml, in the range from about 3 mg/ml to about 10 mg/ml, or in the range from about 5 mg/ml to about 8 mg/ml.
  • insulinotropic peptide is exendin-4 or ZP-IO, i.e. HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2.
  • composition according to any of embodiments 1-32, wherein said insulinotropic peptide is acylated exendin-4 or an acylated exendin-4 analogue.
  • insulinotropic peptide is [N-epsilon(17-carboxyheptadecanoic acid)Lys20 exendin-4(l- 39)-amide
  • compositions 39-41 wherein the concentration of said insulinotropic peptide in the pharmaceutical composition is from about 5 ⁇ g/ml_ to about lOmg/mL, from about 5 ⁇ g/ml_ to about 5mg/ml_, from about 5 ⁇ g/ml_ to about 5mg/ml_, from about O.lmg/mL to about 3mg/ml_, or from about 0.2mg/ml_ to about lmg/mL.
  • the composition is adapted for pulmonary treatment, oral treatment, nasal treatment or buccal treatment.
  • composition according to any one of embodiments 1-42, wherein the composition is adapted for pulmonary use.
  • composition according to any one of embodiments 1-42, wherein the composition is adapted for nasal treatment.
  • composition according to any one of embodiments 1-42, wherein the composition is adapted for oral use.
  • composition according to any one of embodiments 1-42, wherein the composition is adapted for buccal use.
  • a method of treating diabetes in a patient in need of such a treatment comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition according to any one of the embodiments 1-47.
  • a method of delaying or preventing disease progression in type 2 diabetes in a patient in need of such a treatment comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition according to any one of the embodiments 1-47.
  • Thioflavin T (ThT) fibrillation assay Principle and examples
  • Thioflavin T is such a probe and has a distinct fluorescence signature when binding to fibrils [Naiki et al. (1989) Anal. Biochem. 177, 244-249; LeVine (1999) Methods. Enzymol. 309, 274-284].
  • F is the ThT fluorescence at the time t.
  • tO is the time needed to reach 50% of maximum fluorescence.
  • Formation of a partially folded intermediate of the peptide is suggested as a general initiating mechanism for fibrillation. Few of those intermediates nucleate to form a template onto which further intermediates may assembly and the fibrillation proceeds.
  • the lag-time corresponds to the interval in which the critical mass of nucleus is built up and the apparent rate constant is the rate with which the fibril itself is formed.
  • Samples were prepared freshly before each assay. Thioflavin T was added to the samples from a stock solution in H 2 O to a final concentration of 1 ⁇ M. Sample aliquots of 200 ⁇ l were placed in a 96 well microtiter plate (Packard OptiPlateTM-96, white polystyrene). Usually, eight replica of each sample (corresponding to one test condition) were placed in one column of wells. The plate was sealed with Scotch Pad (Qiagen). Incubation and fluorescence measurement
  • Sample preparation and fluorescence measurement Samples containing insulin aspart in non-aqueous propylene glycol was stored at 5 and 40°C for up to 1 month. The samples were prior to measurement diluted to an expected concentration (including fibrillated and native protein) of 1 mg/ml with demineralised water. Fluorescence measurements were performed in semimicro quartz cuvettes (Hellma, Germany) with a 0.3 cm excitation light path using a Perkin-Elmer model LS 50 B luminescence spectrometer. Emission spectra from 470 to 560 nm with excitation at
  • ThT 450 nm and with slit widths of 5 nm were recorded immediately after addition of 4 ⁇ l ThT 1 mM stock solution to 196 ⁇ l diluted sample.
  • concentration of ThT in reaction mixture was 20 ⁇ Mol/l.
  • the results were reported as I 482 nm /[protein concentration (mg/ml) x cuvette path length (cm)], i.e. the results were normalized to a protein concentration of 1 mg/ml and a cuvette path length of 1 cm.
  • composition was the following :
  • Arg34, Lys26(N ⁇ -( ⁇ -Glu(N ⁇ -hexadecanoyl)))-GLP-l(7-37), with a pi of 5.6 and a target pH of of 8.7 was dissolved into the polar co-solvents (propylene glycol, ethanol and water) and filled into a 14 ml glass canister.
  • the canister was closed with a spray valve (Valois, Le Vaudreuil, France) and HFA propellant was filled into the canister with a Pamasol 2005/10 filling machine.
  • the formulation was slightly cloudy, which might be due to trace amounts of insoluble inorganic salts.
  • the particle size distribution was evaluated by laser diffraction analysis (Sympatec GmbH, Germany) equipped with Windox 4 software.
  • Formulations Fl-6 did not show any precipitation of the active immediately after filling; however, all investigated compositions finally showed some kind of precipitate after storage for a few days or after mechanical stress (shaking).
  • the most promising formulation was found to be F6 containing 17.5% ethanol, 12.5% propylene glycol and 67.5% HFA 227. This formulation did not show precipitation until day 21 after manufacture. However, after 3 weeks storage a slight precipitate was observed which was easily redispersable.
  • Table 2 Formulations showing least precipitation and no / minimal glass container adsorption
  • formulation F6 was freshly prepared and sprayed for aerosol droplet size measurement using different actuator orifice diameters.
  • formulation F6 The droplet size distributions of formulation F6 were determined by laser diffraction (HELOS-laser diffractometer, SympaTEC GmbH, Germany). The MDI was positioned in front of the laser beam at a distance of approx. 12 cm. The measurements were performed when the optical concentration of aerosol was > 0.1. The R3 lens (measuring range from 0.5 ⁇ m to 175 ⁇ m) was used. The raw data for the determination of particle size distribution was evaluated by the Sympatec Windox 5 Software according to the Fraunhofer theory. Formulation F6 with 12.5% propylene glycol and 17.5% ethanol showed average particles sizes of roughly 25 ⁇ m and and a d90% of roughly 40 ⁇ m.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques non aqueuses à longue durée de conservation ainsi que leur utilisation dans des méthodes de traitement du diabète et de l'hyperglycémie. Ces compositions comprennent un peptide insulinotropique et un solvant organique protique semi-polaire.
PCT/EP2008/056699 2007-06-01 2008-05-30 Compositions pharmaceutiques non aqueuses stables WO2008145732A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/601,345 US20100190706A1 (en) 2007-06-01 2008-05-30 Stable Non-Aqueous Pharmaceutical Compositions
JP2010509835A JP5675347B2 (ja) 2007-06-01 2008-05-30 安定した非水性薬学的組成物
EP08760287A EP2164459A1 (fr) 2007-06-01 2008-05-30 Compositions pharmaceutiques non aqueuses stables

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07109435.3 2007-06-01
EP07109435 2007-06-01
EP07114524 2007-08-17
EP07114524.7 2007-08-17

Publications (1)

Publication Number Publication Date
WO2008145732A1 true WO2008145732A1 (fr) 2008-12-04

Family

ID=39764679

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2008/056689 WO2008145730A1 (fr) 2007-06-01 2008-05-30 Compositions pharmaceutiques non aqueuses stables
PCT/EP2008/056699 WO2008145732A1 (fr) 2007-06-01 2008-05-30 Compositions pharmaceutiques non aqueuses stables

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/056689 WO2008145730A1 (fr) 2007-06-01 2008-05-30 Compositions pharmaceutiques non aqueuses stables

Country Status (11)

Country Link
US (3) US20100190706A1 (fr)
EP (4) EP2164459A1 (fr)
JP (2) JP5675347B2 (fr)
KR (1) KR20100017667A (fr)
CN (1) CN101677944A (fr)
AU (1) AU2008257505B2 (fr)
BR (1) BRPI0812354A2 (fr)
CA (1) CA2716159A1 (fr)
MX (1) MX2009012789A (fr)
RU (1) RU2472492C2 (fr)
WO (2) WO2008145730A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064316A2 (fr) 2009-11-25 2011-06-03 Paolo Botti Administration de peptides par voie muqueuse
EP2526971A1 (fr) 2011-05-25 2012-11-28 ArisGen SA Administration de médicaments par les muqueuses
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
ES2563038T3 (es) 2007-04-30 2016-03-10 Novo Nordisk A/S Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca
EP2164459A1 (fr) * 2007-06-01 2010-03-24 Novo Nordisk A/S Compositions pharmaceutiques non aqueuses stables
WO2009112583A2 (fr) * 2008-03-14 2009-09-17 Novo Nordisk A/S Analogues de l’insuline stabilisés une protéase
EP2910569B1 (fr) 2008-03-18 2016-10-05 Novo Nordisk A/S Analogues de l'insuline acylés, stabilisés à la protéase
CN102481343A (zh) * 2009-09-16 2012-05-30 诺沃—诺迪斯克有限公司 稳定的含胰岛素的非水液体药物组合物
WO2011086093A2 (fr) 2010-01-12 2011-07-21 Novo Nordisk A/S Compositions pharmaceutiques pour l'administration orale de peptides de l'insuline
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
EP2608771B1 (fr) * 2010-08-23 2018-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions pour administration gastrique d'agents actifs
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
US8853189B2 (en) 2012-05-31 2014-10-07 Prima Innovations, Llc Antispasmodic 1,2-Diols and 1,2,3-triols
US9956287B2 (en) 2013-02-06 2018-05-01 Perosphere Inc. Stable glucagon formulations
PL3055325T3 (pl) 2013-10-07 2018-06-29 Novo Nordisk A/S Nowa pochodna analogu insuliny
EP2946788A1 (fr) 2014-05-23 2015-11-25 Immundiagnostik AG Procédé et composition pour le traitement de l'insuffisance cardiaque avec la fraction d'éjection préservée
EP3154568A4 (fr) 2014-06-10 2018-01-24 California Institute of Technology Insulines non canoniques et leurs utilisations
PT3554534T (pt) 2016-12-16 2021-11-05 Novo Nordisk As Composições farmacêuticas contendo insulina
WO2019006155A1 (fr) * 2017-06-28 2019-01-03 Children's Medical Center Corporation Promotion de la croissance pulmonaire
EP3915571A1 (fr) * 2020-05-29 2021-12-01 Adocia Composition pharmaceutique sous la forme d'une solution aqueuse injectable comprenant au moins un analogue de l'insuline à action rapide et un suppresseur de glucagon à action prandiale
CN114432424B (zh) * 2021-12-27 2023-06-27 南通联亚药业股份有限公司 一种稳定的铝塑包装去氨加压素片剂
WO2024123214A1 (fr) * 2022-12-04 2024-06-13 Общество С Ограниченной Ответственностью "Герофарм" Composition d'insuline asparte (variantes)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002547A1 (fr) * 1998-09-01 2000-05-24 F. Hoffmann-La Roche Ag Complex ionique hydrosoluble de la protein Hedgehog et son utilisation pharmaceutique
US20030035775A1 (en) * 1998-11-19 2003-02-20 Mary Rose Scozzafava Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
WO2004105790A1 (fr) * 2003-06-03 2004-12-09 Novo Nordisk A/S Compositions peptidiques pharmaceutiques stabilisees
US20050276843A1 (en) * 2004-05-10 2005-12-15 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
WO2007047948A2 (fr) * 2005-10-20 2007-04-26 Nastech Pharmaceutical Company Inc. Administration intranasale d'insuline a action rapide

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US221A (en) 1837-06-03 Steam-boii
US6074A (en) 1849-01-30 Machine fob making suspender-buckles
US3003A (en) * 1843-03-17 Improvement in the method of propelling vessels by means of continuous streams of water
US4468A (en) 1846-04-25 Improvement in casting spoons
US2832685A (en) * 1952-05-24 1958-04-29 Crest Foods Co Inc Solubilization of milk proteins
US3528960A (en) * 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) * 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033941A (en) * 1975-12-17 1977-07-05 Eli Lilly And Company Process for purifying glucagon
JPS6030650B2 (ja) * 1979-10-26 1985-07-17 日本油脂株式会社 座薬基剤組成物
US4468221A (en) 1981-04-10 1984-08-28 Parker-Hannifin Corporation Medication infusion pump
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4719655A (en) * 1986-01-21 1988-01-19 Dean S Brooks Invalid transfer device
US4849227A (en) * 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
AU628674B2 (en) * 1989-10-19 1992-09-17 Nippon Oil And Fats Company, Limited Polymer complexes of a sugar response type
US5179189A (en) * 1990-01-19 1993-01-12 Nova Pharmaceutical Corporation Fatty acid terminated polyanhydrides
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5589167A (en) * 1993-02-23 1996-12-31 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
ATE176482T1 (de) 1993-06-21 1999-02-15 Novo Nordisk As Asp-b28-insulinkristalle
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
PT792290E (pt) 1993-09-17 2002-01-30 Novo Nordisk As Insulina acilada
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US6500645B1 (en) * 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US20030104981A1 (en) * 1995-11-03 2003-06-05 Jelena Mandic Human insulin analogues
ZA9610374B (en) 1995-12-11 1997-06-23 Elan Med Tech Cartridge-based drug delivery device
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
EP0821006B1 (fr) * 1996-07-26 2004-04-21 Aventis Pharma Deutschland GmbH Dérivés de l'insuline ayant une activité de liaison au zinc augmentée
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US5957895A (en) 1998-02-20 1999-09-28 Becton Dickinson And Company Low-profile automatic injection device with self-emptying reservoir
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
CN1141974C (zh) * 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
CN1160122C (zh) * 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7186797B2 (en) * 2001-08-10 2007-03-06 Epix Pharmaceuticals, Inc. Polypeptide conjugates with extended circulating half-lives
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
WO2003050276A1 (fr) * 2001-12-05 2003-06-19 Dow Global Technologies Inc. Procede d'immobilisation d'un agent biologique dans une composition de polyurethane-hydrogel, composition preparee a partir de ce procede et applications biomedicales
UA46669C2 (uk) * 2001-12-29 2005-12-15 Товариство З Обмеженою Відповідальністю "Мако" Спосіб приготування готової лікарської форми інсуліну пролонгованої дії
EP1485443B1 (fr) 2002-03-18 2007-01-03 Bespak Plc Materiau d'etancheite pour appareil de distribution
US7601688B2 (en) * 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
AU2003272347A1 (en) * 2002-09-17 2004-04-08 Merck And Co., Inc. Removal of aldehyde impurity by reactive polystyrene resin
JP4463814B2 (ja) * 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
JP5558655B2 (ja) * 2003-11-20 2014-07-23 ノヴォ ノルディスク アー／エス 注入デバイスにおける生成および使用に最適なプロピレングリコール含有ペプチド処方
ES2369895T3 (es) 2003-12-03 2011-12-07 Novo Nordisk A/S Insulina monocatenaria.
US7371381B2 (en) * 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
CA2563533C (fr) * 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capables de faciliter la penetration a travers une barriere biologique
RU2393168C2 (ru) * 2004-07-19 2010-06-27 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
EP1781324A2 (fr) 2004-08-20 2007-05-09 Novo Nordisk A/S Molecules pharmaceutiquement actives modulant le recepteur de l'insuline
EP1909824B1 (fr) * 2005-04-08 2011-05-18 Amylin Pharmaceuticals, Inc. Formulations pharmaceutiques comprenant un peptide incretine et un solvant polaire aprotique
CN101212947A (zh) * 2005-06-30 2008-07-02 阿斯利康(瑞典)有限公司 环境检测器
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
EP2164459A1 (fr) * 2007-06-01 2010-03-24 Novo Nordisk A/S Compositions pharmaceutiques non aqueuses stables
US20090087484A1 (en) * 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
WO2010060667A1 (fr) * 2008-11-28 2010-06-03 Novo Nordisk A/S Compositions pharmaceutiques appropriées pour une administration orale de dérivé de peptide d'insuline

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002547A1 (fr) * 1998-09-01 2000-05-24 F. Hoffmann-La Roche Ag Complex ionique hydrosoluble de la protein Hedgehog et son utilisation pharmaceutique
US20030035775A1 (en) * 1998-11-19 2003-02-20 Mary Rose Scozzafava Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
WO2004105790A1 (fr) * 2003-06-03 2004-12-09 Novo Nordisk A/S Compositions peptidiques pharmaceutiques stabilisees
US20050276843A1 (en) * 2004-05-10 2005-12-15 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
WO2007047948A2 (fr) * 2005-10-20 2007-04-26 Nastech Pharmaceutical Company Inc. Administration intranasale d'insuline a action rapide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2164459A1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064316A2 (fr) 2009-11-25 2011-06-03 Paolo Botti Administration de peptides par voie muqueuse
EP2526971A1 (fr) 2011-05-25 2012-11-28 ArisGen SA Administration de médicaments par les muqueuses
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation

Also Published As

Publication number Publication date
AU2008257505B2 (en) 2013-05-16
JP2010529004A (ja) 2010-08-26
US20100190706A1 (en) 2010-07-29
BRPI0812354A2 (pt) 2015-01-27
RU2009146883A (ru) 2011-07-20
CA2716159A1 (fr) 2008-12-04
EP2164459A1 (fr) 2010-03-24
CN101677944A (zh) 2010-03-24
EP2497462A1 (fr) 2012-09-12
JP2010529956A (ja) 2010-09-02
EP2164458A1 (fr) 2010-03-24
AU2008257505A1 (en) 2008-12-04
KR20100017667A (ko) 2010-02-16
US20140349924A1 (en) 2014-11-27
EP2514407A1 (fr) 2012-10-24
US20100144592A1 (en) 2010-06-10
RU2472492C2 (ru) 2013-01-20
JP5675347B2 (ja) 2015-02-25
WO2008145730A1 (fr) 2008-12-04
MX2009012789A (es) 2009-12-10
JP5628026B2 (ja) 2014-11-19

Similar Documents

Publication Publication Date Title
JP5675347B2 (ja) 安定した非水性薬学的組成物
JP2010529956A5 (fr)
CN1882356B (zh) 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
CN102940879B (zh) 稳定化的药物肽组合物
JP5241849B2 (ja) インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
CN102037008B (zh) 蛋白酶稳定化的、酰化胰岛素类似物
EP1478233B1 (fr) Methode d'administration de molecules peptidiques du type glucagon (glp-1)
EP2060268A1 (fr) Compositions pharmaceutiques pour distribution pulmonaire ou nasale de peptides
US8748376B2 (en) Stable formulations of peptides
CN1812808B (zh) 稳定化的药物肽组合物
EP3295952A1 (fr) Formulation pharmaceutique comprenant un analogue du glp-1 et son procédé de préparation
CN1812807A (zh) 稳定化的药物肽组合物
RU2831321C2 (ru) Пептидная композиция, содержащая пропиленгликоль, являющаяся оптимальной для изготовления и применения в инъекционных устройствах

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08760287

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008760287

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010509835

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12601345

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载